The efficacy and safety of intravitreal conbercept combined with mitomycin C augmented trabeculectomy for treating neovascular glaucoma

Discov Med. 2020 Mar-Apr;29(157):113-118.

Abstract

Aim: To investigate the efficacy and safety of intravitreal Conbercept (IVC) and trabeculectomy for treating neovascular glaucoma (NVG).

Methods: We retrospectively reviewed a total of 29 eyes from 29 NVG patients. All patients received preoperative IVC combined with mitomycin C (MMC) augmented trabeculectomy with a 12-month follow-up. The best-corrected visual acuities (BCVA), intraocular pressure (IOP), and cumulative survival rate were calculated.

Results: All 29 cases had complete regression of iris neovascularization at 7 days after the combination treatment, and 2 cases had residual iris neovascularization which regressed completely 1 month later. IOP decreased while BCVA improved significantly following the combination treatment. The success rates were 96.6%, 93.1%, 89.7%, 86.2%, and 82.8% at 1 week, 1, 3, 6, and 12 months after trabeculectomy, respectively. IVC injection combined trabeculectomy had few complications.

Conclusions: IVC injection of conbercept combined with trabeculectomy is effective and safe for the treatment of NVG.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / administration & dosage*
  • Angiogenesis Inhibitors / adverse effects
  • Combined Modality Therapy / adverse effects
  • Combined Modality Therapy / methods
  • Female
  • Glaucoma, Neovascular / diagnosis
  • Glaucoma, Neovascular / therapy*
  • Humans
  • Intravitreal Injections
  • Iris / blood supply
  • Iris / diagnostic imaging
  • Iris / drug effects
  • Iris / surgery
  • Male
  • Middle Aged
  • Mitomycin / administration & dosage*
  • Mitomycin / adverse effects
  • Recombinant Fusion Proteins / administration & dosage*
  • Recombinant Fusion Proteins / adverse effects
  • Retrospective Studies
  • Trabeculectomy / adverse effects
  • Trabeculectomy / methods*
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Recombinant Fusion Proteins
  • KH902 fusion protein
  • Mitomycin